1MRNA Fundamental Analysis - MODERNA INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to 1MRNA. 1MRNA was compared to 82 industry peers in the Biotechnology industry. 1MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, 1MRNA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 1MRNA has reported negative net income.

In the past year 1MRNA has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: 1MRNA reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of 1MRNA (-25.68%) is comparable to the rest of the industry.

1MRNA's Return On Equity of -33.40% is fine compared to the rest of the industry. 1MRNA outperforms 61.45% of its industry peers.

		Industry Rank	Sector Rank
ROA	-25.68%
ROE	-33.4%
ROIC	N/A

ROA(3y)-6.14%

ROA(5y)4.17%

ROE(3y)-7.66%

ROE(5y)6.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 63.49%, 1MRNA is in line with its industry, outperforming 59.04% of the companies in the same industry.

In the last couple of years the Gross Margin of 1MRNA has declined.

The Profit Margin and Operating Margin are not available for 1MRNA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.49%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.55%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, 1MRNA has more shares outstanding

The number of shares outstanding for 1MRNA has been increased compared to 5 years ago.

1MRNA has a better debt/assets ratio than last year.

2.2 Solvency

1MRNA has an Altman-Z score of 3.40. This indicates that 1MRNA is financially healthy and has little risk of bankruptcy at the moment.

1MRNA's Altman-Z score of 3.40 is fine compared to the rest of the industry. 1MRNA outperforms 72.29% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that 1MRNA is not too dependend on debt financing.

With an excellent Debt to Equity ratio value of 0.00, 1MRNA belongs to the best of the industry, outperforming 90.36% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.4

ROIC/WACCN/A

WACC8.71%

2.3 Liquidity

A Current Ratio of 3.93 indicates that 1MRNA has no problem at all paying its short term obligations.

1MRNA has a Current ratio of 3.93. This is in the better half of the industry: 1MRNA outperforms 73.49% of its industry peers.

A Quick Ratio of 3.73 indicates that 1MRNA has no problem at all paying its short term obligations.

1MRNA has a better Quick ratio (3.73) than 77.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.93
Quick Ratio	3.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for 1MRNA have decreased strongly by -38.66% in the last year.

Looking at the last year, 1MRNA shows a very negative growth in Revenue. The Revenue has decreased by -56.07% in the last year.

The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-38.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1800%

Revenue 1Y (TTM)-56.07%

Revenue growth 3Y-44.04%

Revenue growth 5Y122.01%

Sales Q2Q%-45.44%

3.2 Future

The Earnings Per Share is expected to grow by 16.53% on average over the next years. This is quite good.

1MRNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.90% yearly.

EPS Next Y11.47%

EPS Next 2Y11.1%

EPS Next 3Y13.46%

EPS Next 5Y16.53%

Revenue Next Year-40.97%

Revenue Next 2Y-22.34%

Revenue Next 3Y-11.19%

Revenue Next 5Y11.9%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

1MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

1MRNA's earnings are expected to grow with 13.46% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.1%

EPS Next 3Y13.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 1MRNA!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MODERNA INC

BIT:1MRNA (12/18/2025, 7:00:00 PM)

27.11

+0.34 (+1.25%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06/bmo

Earnings (Next)02-12 2026-02-12/amc

Inst Owners71.57%

Inst Owner ChangeN/A

Ins Owners2.54%

Ins Owner ChangeN/A

Market Cap10.59B

Revenue(TTM)2.23B

Net Income(TTM)-3.12B

Analysts55.86

Price Target29.78 (9.85%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)52.94%

Min EPS beat(2)29.6%

Max EPS beat(2)76.27%

EPS beat(4)3

Avg EPS beat(4)30.21%

Min EPS beat(4)-6.26%

Max EPS beat(4)76.27%

EPS beat(8)7

Avg EPS beat(8)49.68%

EPS beat(12)9

Avg EPS beat(12)9.25%

EPS beat(16)12

Avg EPS beat(16)10.78%

Revenue beat(2)2

Avg Revenue beat(2)17.81%

Min Revenue beat(2)12.36%

Max Revenue beat(2)23.26%

Revenue beat(4)3

Avg Revenue beat(4)8.94%

Min Revenue beat(4)-0.3%

Max Revenue beat(4)23.26%

Revenue beat(8)7

Avg Revenue beat(8)29.87%

Revenue beat(12)10

Avg Revenue beat(12)27.21%

Revenue beat(16)13

Avg Revenue beat(16)22.97%

PT rev (1m)-16.78%

PT rev (3m)-25.19%

EPS NQ rev (1m)0.34%

EPS NQ rev (3m)8.6%

EPS NY rev (1m)17.49%

EPS NY rev (3m)17.66%

Revenue NQ rev (1m)0.88%

Revenue NQ rev (3m)-11.02%

Revenue NY rev (1m)0.05%

Revenue NY rev (3m)-1.02%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.56
P/FCF	N/A
P/OCF	N/A
P/B	1.33
P/tB	1.34
EV/EBITDA	N/A

EPS(TTM)-6.89

EYN/A

EPS(NY)-6.07

Fwd EYN/A

FCF(TTM)-5.82

FCFYN/A

OCF(TTM)-4.32

OCFYN/A

SpS4.88

BVpS20.39

TBVpS20.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.68%
ROE	-33.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.49%
FCFM	N/A

ROA(3y)-6.14%

ROA(5y)4.17%

ROE(3y)-7.66%

ROE(5y)6.83%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.55%

GM growth 5YN/A

F-Score2

Asset Turnover0.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	329.33%
Cap/Sales	30.69%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.93
Quick Ratio	3.73
Altman-Z	3.4

F-Score2

WACC8.71%

ROIC/WACCN/A

Cap/Depr(3y)261.63%

Cap/Depr(5y)224.68%

Cap/Sales(3y)14.96%

Cap/Sales(5y)10.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-38.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1800%

EPS Next Y11.47%

EPS Next 2Y11.1%

EPS Next 3Y13.46%

EPS Next 5Y16.53%

Revenue 1Y (TTM)-56.07%

Revenue growth 3Y-44.04%

Revenue growth 5Y122.01%

Sales Q2Q%-45.44%

Revenue Next Year-40.97%

Revenue Next 2Y-22.34%

Revenue Next 3Y-11.19%

Revenue Next 5Y11.9%

EBIT growth 1Y-46.28%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year17.75%

EBIT Next 3Y15.57%

EBIT Next 5Y17.94%

FCF growth 1Y-0.23%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.81%

OCF growth 3YN/A

OCF growth 5YN/A

MODERNA INC / 1MRNA.MI FAQ

Can you provide the ChartMill fundamental rating for MODERNA INC?

ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI.

What is the valuation status of MODERNA INC (1MRNA.MI) stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (1MRNA.MI). This can be considered as Overvalued.

Can you provide the profitability details for MODERNA INC?

MODERNA INC (1MRNA.MI) has a profitability rating of 2 / 10.

What is the expected EPS growth for MODERNA INC (1MRNA.MI) stock?

The Earnings per Share (EPS) of MODERNA INC (1MRNA.MI) is expected to grow by 11.47% in the next year.

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MODERNA INC / 1MRNA.MI FAQ

Can you provide the ChartMill fundamental rating for MODERNA INC?

What is the valuation status of MODERNA INC (1MRNA.MI) stock?

Can you provide the profitability details for MODERNA INC?

What is the expected EPS growth for MODERNA INC (1MRNA.MI) stock?